Dean W. Felsher - Publications

Stanford University, Palo Alto, CA 
Molecular Biology, Oncology

34 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Li Y, Thomas D, Deutzmann A, Majeti R, Felsher DW, Dill DL. Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index. Scientific Reports. 9: 16775. PMID 31727951 DOI: 10.1038/s41598-019-53290-3  0.52
2018 Lai I, Swaminathan S, Baylot V, Mosley A, Dhanasekaran R, Gabay M, Felsher DW. Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma. Journal For Immunotherapy of Cancer. 6: 125. PMID 30458889 DOI: 10.1186/s40425-018-0431-x  0.52
2016 Li Y, Deutzmann A, Felsher DW. BIM-mediated apoptosis and oncogene addiction. Aging. PMID 27688082 DOI: 10.18632/aging.101072  0.52
2016 Li Y, Deutzmann A, Choi PS, Fan AC, Felsher DW. BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia. Oncotarget. PMID 27095570 DOI: 10.18632/oncotarget.8731  0.52
2016 Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw A, Baylot V, Guetegemann I, Eilers M, Felsher DW. MYC regulates the antitumor immune response through CD47 and PD-L1. Science (New York, N.Y.). PMID 26966191 DOI: 10.1126/science.aac9935  0.52
2015 Goodson WH, Lowe L, Carpenter DO, Gilbertson M, Manaf Ali A, Lopez de Cerain Salsamendi A, Lasfar A, Carnero A, Azqueta A, Amedei A, Charles AK, Collins AR, Ward A, Salzberg AC, Colacci A, ... ... Felsher DW, et al. Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Carcinogenesis. 36: S254-96. PMID 26106142 DOI: 10.1093/carcin/bgv039  0.32
2015 Shroff EH, Eberlin LS, Dang VM, Gouw AM, Gabay M, Adam SJ, Bellovin DI, Tran PT, Philbrick WM, Garcia-Ocana A, Casey SC, Li Y, Dang CV, Zare RN, Felsher DW. MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. Proceedings of the National Academy of Sciences of the United States of America. 112: 6539-44. PMID 25964345 DOI: 10.1073/pnas.1507228112  0.52
2014 Li Y, Casey SC, Choi PS, Felsher DW. miR-17-92 explains MYC oncogene addiction. Molecular & Cellular Oncology. 1: e970092. PMID 27308380 DOI: 10.4161/23723548.2014.970092  0.52
2014 Li Y, Choi PS, Felsher DW. Oncogene addiction: resetting the safety switch? Oncotarget. 5: 7986-7. PMID 25275297  0.52
2014 Li Y, Choi PS, Casey SC, Felsher DW. Activation of Cre recombinase alone can induce complete tumor regression. Plos One. 9: e107589. PMID 25208064 DOI: 10.1371/journal.pone.0107589  0.52
2014 Li Y, Choi PS, Casey SC, Dill DL, Felsher DW. MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state. Cancer Cell. 26: 262-72. PMID 25117713 DOI: 10.1016/j.ccr.2014.06.014  0.52
2014 Casey SC, Li Y, Fan AC, Felsher DW. Oncogene withdrawal engages the immune system to induce sustained cancer regression. Journal For Immunotherapy of Cancer. 2: 24. PMID 25089198 DOI: 10.1186/2051-1426-2-24  0.52
2014 Choi PS, Li Y, Felsher DW. Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance. Proceedings of the National Academy of Sciences of the United States of America. 111: E3316-24. PMID 25071175 DOI: 10.1073/pnas.1406123111  0.52
2014 Eberlin LS, Gabay M, Fan AC, Gouw AM, Tibshirani RJ, Felsher DW, Zare RN. Alteration of the lipid profile in lymphomas induced by MYC overexpression. Proceedings of the National Academy of Sciences of the United States of America. 111: 10450-5. PMID 24994904 DOI: 10.1073/pnas.1409778111  0.52
2014 Gabay M, Li Y, Felsher DW. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harbor Perspectives in Medicine. 4. PMID 24890832 DOI: 10.1101/cshperspect.a014241  0.52
2014 Casey SC, Li Y, Felsher DW. An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation. Immunologic Research. 58: 282-91. PMID 24791942 DOI: 10.1007/s12026-014-8503-6  0.52
2011 Tran PT, Bendapudi PK, Lin HJ, Choi P, Koh S, Chen J, Horng G, Hughes NP, Schwartz LH, Miller VA, Kawashima T, Kitamura T, Paik D, Felsher DW. Survival and death signals can predict tumor response to therapy after oncogene inactivation. Science Translational Medicine. 3: 103ra99. PMID 21974937 DOI: 10.1126/scitranslmed.3002018  0.48
2011 Choi PS, van Riggelen J, Gentles AJ, Bachireddy P, Rakhra K, Adam SJ, Plevritis SK, Felsher DW. Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. Proceedings of the National Academy of Sciences of the United States of America. 108: 17432-7. PMID 21969595 DOI: 10.1073/pnas.1107303108  0.48
2010 Rakhra K, Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A, Fan AC, Yang Q, Braunstein L, Crosby E, Ryeom S, Felsher DW. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell. 18: 485-98. PMID 21035406 DOI: 10.1016/j.ccr.2010.10.002  0.48
2010 Contag CH, Sikorski R, Negrin RS, Schmidt T, Fan AC, Bachireddy P, Felsher DW, Thorne SH. Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells. Cancer Research. 70: 9837-45. PMID 20935221 DOI: 10.1158/0008-5472.CAN-10-2650  0.48
2008 Arvanitis C, Bendapudi PK, Tseng JR, Gambhir SS, Felsher DW. (18)F and (18)FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation. Cancer Biology & Therapy. 7: 1947-51. PMID 18981708  1
2008 Fan AC, Goldrick MM, Ho J, Liang Y, Bachireddy P, Felsher DW. A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice. Molecular Cancer. 7: 74. PMID 18826639 DOI: 10.1186/1476-4598-7-74  0.48
2008 Wu CH, Sahoo D, Arvanitis C, Bradon N, Dill DL, Felsher DW. Combined analysis of murine and human microarrays and ChIP analysis reveals genes associated with the ability of MYC to maintain tumorigenesis. Plos Genetics. 4: e1000090. PMID 18535662 DOI: 10.1371/journal.pgen.1000090  1
2008 Tran PT, Fan AC, Bendapudi PK, Koh S, Komatsubara K, Chen J, Horng G, Bellovin DI, Giuriato S, Wang CS, Whitsett JA, Felsher DW. Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. Plos One. 3: e2125. PMID 18461184 DOI: 10.1371/journal.pone.0002125  0.48
2007 Wu CH, van Riggelen J, Yetil A, Fan AC, Bachireddy P, Felsher DW. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proceedings of the National Academy of Sciences of the United States of America. 104: 13028-33. PMID 17664422 DOI: 10.1073/pnas.0701953104  0.48
2007 Arvanitis C, Bendapudi PK, Bachireddy P, Felsher DW. Identifying critical signaling molecules for the treatment of cancer. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. ProgrèS Dans Les Recherches Sur Le Cancer. 172: 5-24. PMID 17607933  1
2006 Giuriato S, Ryeom S, Fan AC, Bachireddy P, Lynch RC, Rioth MJ, van Riggelen J, Kopelman AM, Passegué E, Tang F, Folkman J, Felsher DW. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proceedings of the National Academy of Sciences of the United States of America. 103: 16266-71. PMID 17056717 DOI: 10.1073/pnas.0608017103  0.48
2006 Arvanitis C, Felsher DW. Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Seminars in Cancer Biology. 16: 313-7. PMID 16935001 DOI: 10.1016/j.semcancer.2006.07.012  1
2005 Arvanitis C, Felsher DW. Conditionally MYC: insights from novel transgenic models. Cancer Letters. 226: 95-9. PMID 16039948 DOI: 10.1016/j.canlet.2004.10.043  1
2005 Bachireddy P, Bendapudi PK, Felsher DW. Getting at MYC through RAS. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 4278-81. PMID 15958607 DOI: 10.1158/1078-0432.CCR-05-0534  0.48
2004 Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop JM, Contag CH, Felsher DW. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature. 431: 1112-7. PMID 15475948 DOI: 10.1038/nature03043  1
2004 Beer S, Zetterberg A, Ihrie RA, McTaggart RA, Yang Q, Bradon N, Arvanitis C, Attardi LD, Feng S, Ruebner B, Cardiff RD, Felsher DW. Developmental context determines latency of MYC-induced tumorigenesis Plos Biology. 2. PMID 15455033 DOI: 10.1371/journal.pbio.0020332  1
2003 Felsher DW, Bradon N. Pharmacological inactivation of MYC for the treatment of cancer. Drug News & Perspectives. 16: 370-4. PMID 12973448  0.32
2002 Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science (New York, N.Y.). 297: 102-4. PMID 12098700 DOI: 10.1126/science.1071489  1
Show low-probability matches.